STOCK TITAN

Evolv Technologies Holdings (EVLV) 8-K Filings

EVLV NASDAQ

Here are the 8-K filings from Evolv Technologies Holdings, Inc. (EVLV) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An 8-K covers material events a company has to report between its quarterly reports, so if you follow EVLV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVLV filings page.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. (EVLV) reported third-quarter 2026 revenue of $47.3 million, up 10% from $42.9 million a year earlier, and ending ARR of $140.5 million, up 20%. Net loss was $15.6 million, compared with $1.8 million; Adjusted EBITDA was $4.7 million versus $5.1 million. For the first nine months, revenue was $137.4 million versus $107.4 million, and net loss narrowed to $29.9 million from $44.0 million. Operating cash flow for the nine months was $26.685 million, compared with $3.098 million.

For 2026, Evolv expects revenue of $182 million to $185 million, depending on the mix of new unit deployments between purchase subscription and pure subscription models. It expects year-end ARR of approximately $148 million to $150 million and Adjusted EBITDA of $15.5 million to $16.5 million, with margins in the high single digits. The outlook is based on current indications, which may change at any time. Cash, cash equivalents and marketable securities totaled $66.9 million as of September 30, 2026; remaining performance obligations were $325.8 million, up $13.2 million sequentially. Evolv cites risks related to material weaknesses in internal control over financial reporting and its remediation efforts.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. appointed Jason Blessing, age 55, as a Class III director effective November 6, 2026; he is to serve until the 2027 annual meeting of stockholders. The board also appointed him to the Audit Committee and the Nominating and Corporate Governance Committee. It determined he satisfies applicable independence requirements, including those for audit committee membership, and qualifies as an “audit committee financial expert.”

Blessing has more than 30 years of experience, including serving as CEO of Model N from May 2018 to September 2024 and CEO of Plex Systems from January 2013 to December 2017. He currently serves as Executive Chair of Mosai, a director of eClinical Solutions and Parsec Automation, and an advisor to AptEdge’s CEO. He will be eligible for compensation under Evolv’s Non-Employee Director Compensation Policy.

Rhea-AI Summary

Evolv Technologies Holdings reported strong second-quarter 2026 results, with revenue of $43.8 million, up 34% year-over-year, and Annual Recurring Revenue of $132.7 million, up 20%. The company added 70 new customers and ended the quarter with Remaining Performance Obligation of $312.6 million.

Net loss narrowed to $(9.3) million, or $(0.05) per share, from $(40.5) million a year earlier, while Adjusted EBITDA improved to $4.4 million from $2.1 million, yielding a 10.1% Adjusted EBITDA margin. For the first six months of 2026, revenue was $90.1 million, up 40% year-over-year, with Adjusted EBITDA of $8.4 million.

The company ended June 30, 2026 with $63.4 million in cash, cash equivalents, marketable securities, and restricted cash, up $2.3 million sequentially, and generated $8.7 million of operating cash flow in the first half. Management raised 2026 guidance, now expecting total revenue of $180–$185 million and ending ARR of $148–$150 million, and targets Adjusted EBITDA of $15–$16 million with margins in the high single digits.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. reported that the U.S. District Court for the District of Massachusetts has preliminarily approved a global settlement of multiple stockholder derivative matters brought on the Company’s behalf. The settlement, documented in an August 5, 2026 stipulation, covers the consolidated federal derivative action, two related Delaware Court of Chancery derivative actions, and a stockholder litigation demand.

The settlement provides for a package of corporate governance reforms, including amendments to the Audit Committee Charter, Marketing Policy, Disclosure Committee Charter, and Corporate Governance Guidelines, creation of a management-level compliance committee, and enhanced roles for the General Counsel in legal and compliance oversight. These reforms will be implemented within 30 days of the settlement’s effective date and maintained for five years. The settlement does not require any payment by Evolv; plaintiffs’ attorneys’ fees and expenses of $1,275,000 are to be paid by the Company’s insurers. A settlement hearing is scheduled for October 21, 2026, and current stockholders as of August 5, 2026 may object or be heard subject to specified procedures.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. reported results of its annual stockholder meeting held on June 18, 2026. A total of 138,936,379 shares of Class A common stock were represented, equal to approximately 77.35% of shares outstanding as of the April 24, 2026 record date.

Stockholders elected Class II directors Neil Glat and Richard Shapiro to serve until the 2029 annual meeting. They also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026.

Rhea-AI Summary

Evolv Technologies Holdings is clarifying that some market data sites misreported its recent revenue figures and outlook. The company confirms Q1 2026 total revenue was $46.3 million, up from $32.0 million in Q1 2025, a 45% year-over-year increase.

Evolv also confirms it has raised its full-year 2026 total revenue guidance range to $175 million to $180 million. The update is meant to ensure investors are relying on the company’s own disclosures rather than incorrect third-party data.

Rhea-AI Summary

Evolv Technologies Holdings reported strong first quarter 2026 results with revenue of $46.3 million, up 45% from $32.0 million a year earlier, driven by new customers and expanded deployments. Ending ARR reached $127.3 million, a 20% year-over-year increase, underscoring growth in recurring subscription-based business.

The company posted a net loss of $5.0 million, or $0.03 per share, compared with a $1.7 million loss, or $0.01 per share, in the prior-year quarter, but improved profitability on an adjusted basis. Adjusted EBITDA rose to $3.9 million from $2.1 million, delivering an 8.5% margin.

Management raised its 2026 total revenue outlook to a range of $175 million to $180 million, reflecting about 20% to 23% year-over-year growth, while reaffirming expectations for year-end ARR of $145 million to $150 million and positive full-year adjusted EBITDA with high single-digit margins.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. reported strong fourth quarter and full-year 2025 results and raised its outlook for 2026. Q4 2025 revenue reached $38.5 million, up 32% year over year, with ending ARR of $120.5 million, up 21%. The company generated Q4 net income of $10.9 million and Adjusted EBITDA of $1.8 million.

For 2025, revenue grew to $145.9 million, a 40% increase from 2024, while net loss narrowed to $33.1 million and Adjusted EBITDA improved to $11.1 million. Operating activities provided $18.7 million of cash, and cash, cash equivalents and marketable securities totaled $69.0 million at year-end.

For 2026, the company expects total revenue of $172–$178 million and ending ARR of $145–$150 million, with positive full-year Adjusted EBITDA and margins in the high single digits, driven by a higher mix of recurring subscription revenue.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. announced a Board change, with long-time director and early venture investor Bilal Zuberi resigning to pursue other endeavors, with no disagreements cited with leadership or the Board.

The company appointed Henrik Kühl, age 46, to its Board of Directors effective February 12, 2026, as a Class III director through the 2027 annual meeting. He will also serve on the Audit Committee. The Board determined that Kühl is independent under Nasdaq and SEC rules and qualifies as an “audit committee financial expert.”

Kühl brings more than 25 years of experience in corporate strategy and development, including his current role as Senior Vice President, Strategy & Corporate Development at Axon. He will receive compensation as a non-employee director under Evolv’s Director Compensation Policy.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. reported that it announced financial results for the fiscal quarter ended September 30, 2025. The company furnished the full press release as Exhibit 99.1 to this Form 8-K.

The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. filed a current report describing two developments. The company announced that it released its financial results for the fiscal quarter ended June 30, 2025, with the full details provided in a separate press release furnished as an exhibit.

The company also reported that Michael Ellenbogen, its Chief Innovation Officer and a member of the Board of Directors, informed the company on August 13, 2025 that he will resign from his Chief Innovation Officer role effective September 5, 2025, citing new time commitments. His decision is stated to be not due to any disagreements with the company. He will continue to serve as a member of the Board and will receive compensation as a non-employee director under the company’s director compensation policy.